Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Luteolin
41
CHF
CHF 41.00
In stock
CDX-L0087-M01010 mgCHF 41.00
CDX-L0087-M05050 mgCHF 102.00
| Product Details | |
|---|---|
| Synonyms | 3',4',5,7-Tetrahydroxyflavone; Luteolol; BRN 0292084; C.I. Natural Yellow 2; Digitoflavone; Flacitran; Flavopurpol; Daphneflavonol; Argemexitin |
| Product Type | Chemical |
| Properties | |
| Formula | C15H10O6 |
| MW | 286.24 |
| CAS | 491-70-3 |
| RTECS | LK9275210 |
| Purity Chemicals | ≥98% (TLC) |
| Appearance | Yellow powder. |
| Solubility | Soluble in DMSO (10mg/ml), DMF (20mg/ml), methanol or ethanol (5mg/ml). Slightly soluble in water. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | IQPNAANSBPBGFQ-UHFFFAOYSA-N |
| Smiles | OC1=C2C(OC(C3=CC(O)=C(O)C=C3)=CC2=O)=CC(O)=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Luteolin is a hydroxylated flavone derivative that is a strong antioxidant and radical scavenger. It has multiple activities, such as anticancer, antimetastatic, anti-adipogenic, anti-inflammatory and neuroprotective. Luteolin has been described as a fatty acid synthase (FASN), 15-lipoxygenase, α-glucosidase, PPAR-γ, topoisomerase I, PI3K/Akt, RSK1/RSK2 and HDAC inhibitor.
Product References
(1) Y.T. Huang, et al.; Br. J. Pharmacol. 128, 999 (1999) | (2) J.S. Kim, et al.; Biosci. Biotechnol. Biochem. 64, 2458 (2000) | (3) H. Ueda, et al.; Biol. Pharm. Bull. 25, 1197 (2002) | (4) A.R. Chowdhury, et al.; Biochem. J. 366, 653 (2002) | (5) L. Sartor, et al.; Biochem. Pharmacol. 64, 229 (2002) | (6) C.D. Sadik, et al.; Biochem. Pharmacol. 65, 773 (2003) | (7) D.T. Coleman, et al.; Mol. Cancer Ther. 8, 214 (2009) | (8) K. Xu, et al.; Molecules 14, 3486 (2009) | (9) H.S. Park, et al.; Biofactors 35, 373 (2009) | (10) S. Attoub, et al.; Eur. J. Pharmacol. 651, 18 (2011) | (11) H.Y. Kim, et al.; Phytother. Res. 27, 1481 (2013) | (12) K.M. Reipas, et al.; Oncotarget 4, 329 (2013)